Gene therapy, in which the coding sequence of truncated versions of Dp427m (micro-dystrophins, only containing several essential protein domains) is systemically delivered via adeno-associated viral vectors (AAVs), is theoretically applicable to all individuals with DMD. Here, DMD is linked to Duchenne muscular dystrophy.